tbuckley/cabot-search huggingface dataset:
<i>In Vivo</i> Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates
Authors: Hua Wang, Li Tang, Yang Liu, Iwona Teresa Dobrucki, Lawrence W. Dobrucki, Lichen Yin, Jianjun Cheng
Journal: Theranostics (2016)

Unnatural sugar-mediated metabolic labeling of cancer cells, coupled with efficient Click chemistry, has shown great potential for in vivo imaging and cancer targeting. Thus far, chemical labeling of cancer cells has been limited to the small-sized azido groups, with the large-sized and highly hydrophobic dibenzocyclooctyne (DBCO) being correspondingly used as the targeting ligand. However, surface modification of nanomedicines with DBCO groups often suffers from low ligand density, difficult functionalization, and impaired physiochemical properties. Here we report the development of DBCO-bearing unnatural sugars that could directly label LS174T colon cancer cells with DBCO groups and subsequently mediate cancer-targeted delivery of azido-modified silica nanoconjugates with easy functionalization and high azido density in vitro and in vivo. This study, for the first time, demonstrates the feasibility of metabolic labeling of cancer cells with large-sized DBCO groups for subsequent, efficient targeting of azido-modified nanomedicines.
Difference In Erythrocyte Alloantibodies After Blood Transfusion In Patients With Hematological and Non-Hematological Diseases
Authors: Daisuke Shimizu, Harumi Fujihara, Hiroki Shibata, Chiaki Yamada, Hiroyuki Furumaki, Hiroko Watanabe, Keiko Ishizuka, Takaaki Ono, Kimiyoshi Sakaguchi, Tsutomu Ogata, Akihiro Takeshita
Journal: Blood (2013)
The Chlamydia surveillance system in Sweden delivers relevant and accurate data: results from the system evaluation, 1997-2008
Authors: M Riera-Montes, I Velicko
Journal: Eurosurveillance (2011)

This study evaluates the ability of the Chlamydia surveillance system to provide relevant information to inform prevention and control activities in Sweden. The system was evaluated, according to the Guidelines for Evaluating Public Health Surveillance Systems from the United States Centers for Disease Prevention and Control, using surveillance data from 1997 to 2008. We interviewed staff from the Swedish Institute for Communicable Disease Control, the National Board of Health and Welfare and one county medical officer (CMO). We conducted a survey among laboratories, CMOs and a sample of clinics. Satisfaction with the system was good for 86% of CMOs, all laboratories, and 99% of clinics. The interviewed stakeholders considered the system to deliver relevant and accurate information that is useful for health policy decision making. However, the objectives for Chlamydia surveillance should be clearly defined in order to adapt the system requirements, simplify data collection and improve timeliness.
TB-25LIMITED AUTOPSY IN PEDIATRIC BRAIN TUMOR PATIENTS WITH A COMPREHENSIVE MULTI-DISCIPLINARY APPROACH RESULTS IN PARENTAL SATISFACTION AND SCIENTIFIC INNOVATION
Authors: Mariko DeWire, Trent Hummel, Lionel Chow, Lindsey Hoffman, Ralph Salloum, Rachid Drissi, Qing Lu, Biplab Dasgupta, Mandy Bley, Bridget Kikta, Aimee Thompson, Susan Jelinek, Nancy Yanez-Escorza, Daniel Heinbaugh, Blaise Jones, James Leach, Lili Miles, Christine Fuller, David Witte, Maryam Fouladi
Journal: Neuro-Oncology (2016)
Locally Advanced Small-Bowel Adenocarcinoma Missed Primarily by Capsule Endoscopy but Diagnosed by Push Enteroscopy
Authors: A Madisch, W Schimming, F Kinzel, R Schneider, D Aust, D M Ockert, M Laniado, G Ehninger, S Miehlke
Journal: Endoscopy (2003)

Wireless-capsule-endoscopy is a new painless method that is able both to visualize the entire small bowel and to detect even small lesions. We report here the case of a patient in whom a locally advanced small-bowel adenocarcinoma was initially missed on capsule endoscopy, but was diagnosed by subsequent push enteroscopy. Capsule endoscopy was carried out in a 47-year-old patient with a history of obscure gastrointestinal bleeding, iron-deficiency anemia, and a lack of symptoms suggestive of stenosis. The capsule imaging revealed angiodysplasias in the jejunum, but no other abnormalities. Push enteroscopy was carried out to allow argon plasma coagulation treatment of the angiodysplasias that had been detected; it revealed a polypoid tumor 20 mm in diameter at 150 cm from the incisors, with the capsule endoscope still located proximal to the tumor and with its optical dome turned towards the push enteroscope. Clinical staging and subsequent surgical resection showed a locally advanced adenocarcinoma (pT4, pN0 (0/7), pMx, G3).Small-bowel tumors within the reach of push enteroscopy may be missed by capsule endoscopy. Although wireless capsule endoscopy is a major advance in the investigation of the small bowel, well-designed clinical studies still need to define the precise algorithm for diagnostic work-up of suspected small-bowel diseases.
Therapeutic effects of methadone and 1-alpha-acetylmethadol
Authors: E Karp-Gelernter, L Wurmser, C Savage
Journal: American Journal of Psychiatry (1976)

Many heroin addicts prefer methadone maintenance treatment to 1-alpha-acetylmethadol(LAAM) because of the "rush-like" effect of methadone. Although there have been no observable differences in the safety and effectiveness of the two drugs, LAAM appears to lead to a more stable, consistent physiological state. The authors report on two patients who had ego defects characterized by severe mood swings. Both patients preferred LAAM to methadone because of its stabilizing effect and smoother action.
Testicular Cancer
Authors: Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, Jue Wang
Journal: Journal of the National Comprehensive Cancer Network (2009)

An estimated 8090 new cases of testicular cancer will be diagnosed in the United States in 2008. 1 Germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes.These tumors also occur occasionally in extragonadal primary sites, but they are still managed the same as testicular GCTs.Although GCTs are relatively uncommon tumors that comprise only 2% of all human malignancies, they constitute the most common solid tumor in men between the ages of 15 and 34 years.In addition, the worldwide incidence of these tumors has more than doubled in the past 40 years.Several risk factors for GCT development have been identified, including prior history, positive family history, cryptorchidism, testicular dysgenesis, and
THE POLIOMYELITIS EPIDEMIC.
Authors: R BERGMAN
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sexual transmission of Zika virus in Germany, April 2016
Authors: Christina Frank, Daniel Cadar, Alexander Schlaphof, Neele Neddersen, Stephan Günther, Jonas Schmidt-Chanasit, Dennis Tappe
Journal: Eurosurveillance (2016)

Zika virus (ZIKV), an emerging mosquito-borne flavivirus, causes a mild dengue fever-like illness but has recently been associated with neurological disease and severe birth defects. The virus is currently causing a large epidemic in the Americas. Here, we report a male-to-female sexual transmission of ZIKV in Germany in April 2016, following travel to Puerto Rico of the male patient, demonstrated by subsequent seroconversions and molecular identification of identical virus sequences from both patients.
GC-10A PROPOSED PATHWAY TOWARDS NON-INVASIVE microRNA-BASED DIAGNOSIS AND RISK STRATIFICATION OF CNS MALIGNANT GERM CELL TUMOURS
Authors: Emma Bell, Hannah Watson, Shivani Bailey, Isabella Syring, Jorg Ellinger, James Nicholson, Helen Brown, Benoit Destenaves, Nicholas Coleman, Matthew Murray
Journal: Neuro-Oncology (2016)
Note on Improved Technique for Production of Cast Masses of Hydra Tissue of Known Volume
Authors: Harold W. Chalkley
Journal: JNCI Journal of the National Cancer Institute (1947)

Journal Article Note on Improved Technique for Production of Cast Masses of Hydra Tissue of Known Volume Get access Harold W. Chalkley Harold W. Chalkley National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 8, Issue 1, August 1947, Page 23, https://doi.org/10.1093/jnci/8.1.23 Published: 01 August 1947 Article history Received: 15 May 1947 Published: 01 August 1947
A new traction method with use of the snare as a “second hand” during endoscopic submucosal dissection
Authors: Peng Jin, Yang Yu, Kuang-I Fu, Dong-liang Yu, Ai-qin Li, Jian-qiu Sheng
Journal: Endoscopy (2015)

Adequate tissue tension and a clear view of the tissue to be dissected are important for effective and safe endoscopic submucosal dissection (ESD). Therefore, various traction methods have been developed to make ESD safer and faster, such as the clip-with-line method [1], magnetic anchor method [2], and double-scope method [3]. Here, a standard snare, often used for polypectomy, serves as a "second hand" (i. e., "traction device") to assist during ESD ([Video 1]).
Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC)
Authors: Junaid Abdulghani, Prashanth Gokare, Jean-Nicolas Gallant, David Dicker, Tiffany Whitcomb, Timothy Cooper, Jiangang Liao, Jonathan Derr, Jing Liu, David Goldenberg, Niklas K. Finnberg, Wafik S. El-Deiry
Journal: Clinical Cancer Research (2016)

Anaplastic thyroid cancer (ATC) comprises approximately 2% of all thyroid cancers, and its median survival rate remains poor. It is responsible for more than one third of thyroid cancer-related deaths. ATC is frequently resistant to conventional therapy, and NFκB signaling has been proposed to be a feature of the disease. We aimed to assess the activity of the antimalaria drug quinacrine known to target NFκB signaling in combination with the clinically relevant kinase inhibitor sorafenib in ATC cells. The presence of NFκB-p65/RELA and its target MCL1 was demonstrated in ATC by meta-data gene set enrichment analysis and IHC. We assessed the responses of a panel of human ATC cell lines to quinacrine and sorafenib in vitro and in vivo RESULTS: We detected increased expression of NFκB-p65/RELA and MCL1 in the nucleus of a subset of ATC compared with non-neoplastic thyroid. ATC cells were found to respond with additive/synergistic tumor cell killing to the combination of sorafenib plus quinacrine in vitro, and the drug combination improves survival of immunodeficient mice injected orthotopically with ATC cells as compared with mice administered either compound alone or doxorubicin. We also demonstrate that the combination of sorafenib and quinacrine is well tolerated in mice. At the molecular level, quinacrine and sorafenib inhibited expression of prosurvival MCL1, pSTAT3, and dampened NFκB signaling.The combination of quinacrine and sorafenib targets emerging molecular hallmarks of ATC and shows promising results in clinically relevant models for the disease. Further testing of sorafenib plus quinacrine can be conducted in ATC patients. Clin Cancer Res; 22(24); 6192-203. ©2016 AACR.
Effects of <i>BRCA1/2</i> on Ovarian and Breast Cancer Survival—Letter
Authors: Li Gong, Chao Dong, Wen Ouyang
Journal: Clinical Cancer Research (2015)

We read the article by Zhong and colleagues (1) with great interest. We sincerely appreciate the tremendous effort made by the authors for presenting this extremely valuable outcome. However, some worthwhile issues also need to be explored.First, the authors need to interpret the results with caution when isolating the HRs and CIs for survival due to the different median follow-up times. Although the patients were followed up to 10 years in references 8 and 11, patients in some other studies were followed up to only 5 years, such as references 5, 9, and 10. Interestingly, when the authors isolated the HRs and CIs for survival associated with mutation in BRCA1 or BRCA2 from reference 7, the adjusted HRs for 5-year survival, rather than 10-year survival, were chosen. Anyway, the authors did not provide the methods of standardization or stratification. Therefore, the HRs and CIs may not be meaningful and cannot really be interpreted.In addition, when the authors calculated the HRs and CIs from the Kaplan–Meier curves in reference 41, an HR of 0.68 (95% CI, 0.43–1.07) means the overall survival was not significantly better in BRCA1 carriers than that for mutation-negative ones. Surprisingly, the original data from reference 41 are that BRCA1-linked cases survived significantly longer than sporadic cases (P = 0.008). We think that the authors should describe why the conclusions are contradictory.Last but not least, prospective and retrospective studies are two fundamental but different kinds of research endeavors (2). As in this article, 20 studies are retrospective studies, and only 7 are prospective. Thus, it is worth mentioning that if the design types could be added into the subgroup analysis, the data could be presented in a more convincing way. In addition, the authors mistook “0.70 (0.36–1.38)” for “0.70 (0.36–1.36),” “1.16 (0.72–1.87)” for “1.16 (0.72–1.85)” and “0.20 (0.06–0.65)” for “0.20 (0.06–0.67)” in Fig. 2, or these may be typos. Above all, we respect the contribution of the authors and we do not doubt the reliability of the measurements.See the Response, p. 3807No potential conflicts of interest were disclosed.This work is supported by the National Natural Science Foundation of China (grant 81172200).
Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia
Authors: Kathryn G. Roberts, Yongjin Li, Debbie Payne-Turner, Richard C. Harvey, Jinjun Cheng, Jinghui Zhang, Guangchun Song, Yung-Li Yang, Natalia Santiago-Morales, Deqing Pei, Cheng Cheng, Jing Ma, Shann-Ching Chen, Michael Rusch, Pankaj Gupta, Meenakshi Devidas, I-Ming Chen, Eric C. Larsen, Naomi J. Winick, William L. Carroll, Nyla A. Heerema, Andrew J. Carroll, Julie M. Gastier-Foster, Elizabeth A. Raetz, Ching-Hon Pui, Sima Jeha, James R Downing, Elisabeth Paietta, Steven M. Kornblau, Guido Marcucci, Clara D. Bloomfield, Daniela S. Gerhard, Mignon L. Loh, Cheryl L. Willman, Stephen P. Hunger, Charles G. Mullighan
Journal: Blood (2013)
Depressive illness in children.
Authors: S A Husain
Journal: BMJ (1971)

for human growth hormone.6The synthesis was performed with the aid of an automated instrument which links amino- acid derivatives one by one to the first amino-acid attached to a solid resin support.7The individual steps were not completely efficient, and further treatments were necessary to remove the solid support and introduce two disulphide linkages.This resulted in a low yield of protein with chemical properties similar to the naturally occurring hormone.The biological activity of the product was low, being approximately 10% of the growth-promoting activity and 5%, of the prolactin activity of growth hormone isolated from human pituitaries.Nevertheless these studies provide additional evidence that the same hormone possesses both growth-promoting and prolactin activities.Synthetic human growth hormone prepared by this method is not of satisfactory purity or of sufficient yield to be of use for the treatment of patients.The potency of highly purified naturally occurring human growth hormone is about 2 IU/mg.Preparations of about half this potency are used in Britain for the treatment of dwarfed children in doses varying from 10 IU to 60 IU per week.' Efficient extraction procedures yield approximately 9 IU from a single pituitary gland,8 which provides considerably more growth-promoting activity than was obtained by the laborious and very expensive synthetic method.It can be expected, therefore, that the requirement for growth hormone prepared from human pituitaries will continue for a long time to come.
Outcome of panic disorder with or without concomitant depression: A 2- year prospective follow-up study
Authors: M Albus, G Scheibe
Journal: American Journal of Psychiatry (1993)

In a prospective 2-year follow-up study, 32 patients with panic disorder alone and 20 with panic disorder and concomitant depression were investigated. After controlled treatment with either imipramine or doxepin, patients received naturalistic treatment with antidepressants, benzodiazepines, and supportive psychotherapy. They were evaluated for anxiety, depression, and social disability at least every 3 months during the follow-up period. The data showed fluctuation of symptoms in both groups and a less favorable outcome for the patients with comorbid conditions. However, the overall outcome was better than that reported in other studies and indicates that panic disorder is quite responsive to appropriate treatment.
유전자 1형 만성 C형간염 환자에서 페그인터페론과 리바비린의 24주와 48주 치료 효과 비교
Authors: 김미나 ( Mi Na Kim ), 윤기태 ( Ki Tae Yoon ), 박준용 ( Jun Yong Park ), 김도영 ( Do Young Kim ), 안상훈 ( Sang Hoon Ahn ), 전재윤 ( Chae Yoon Chon ), 한광협 ( Kwang Hyub Han )
Journal: Clinical and Molecular Hepatology (2009)

목적: 유전자 1형 만성 C형간염의 표준치료는 페그인터페론과 리바비린의 48주 병합요법이다. 치료에 따르는 부작용과 비용 때문에 가장 적절한 치료기간을 찾고자 하는 연구들이 시도되고 있다. 본 연구에서는 유전자 1형 만성 C형간염 환자에서 페그인터페론과 리바비린 병합요법으로 24주 또는 48주 동안 치료한 성적을 알아보고, 분할 24주 치료(24주 치료한 환자에서 재발한 환자를 대상으로 추가 24주 치료를 시행)의 효과에 대해 알아보고자 하였다. 대상과 방법: 130명의 유전자 1형 만성 C형간염 환자를 대상으로 하였다. 치료 후 24주째에 HCV RNA 정성검사를 시행하여, HCV RNA가 음성으로 나온 환자들에서 24주 또는 48주의 치료기간을 결정하였다. 52명의 환자가 24주 치료를 선택하였으며, 50명의 환자가 48주 치료를 선택하였다. 24주 치료를 선택한 환자에서 치료 종료 후 재발이 확인된 환자는 추가 24주 치료를 받도록 하였다. 각 치료군에서 지속바이러스반응(sustained virologic response, SVR)률을 분석하였다. 결과: 48주 치료군의 SVR률(74.0%)이 24주 치료군의 SVR률(52.9%)보다 높았다. SVR에 영향을 미치는 요인에 대한 다변량 분석에서 50세 미만, 혈소판 수치 15만 이하 및 48주 치료기간이 SVR에 영향을 주는 독립적인 인자로 나타났다. 24주 치료군 중 재발한 24명 중 14명이 분할 24주 치료를 마쳤으며, 6명에서 SVR이 추가로 확인되었다. 결론: 본 연구의 결과는 유전자 1형 환자 중 선택된 환자들에서 24주 치료를 시도할 수 있고, 분할 24주 치료가 24주 치료를 시도할 수 있는 유용한 근거가 될 수 있음을 보여준다.
Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts
Authors: I. García-Doval, M.V. Hernández, F. Vanaclocha, A. Sellas, P. de la Cueva, D. Montero
Journal: British Journal of Dermatology (2016)

Information on the safety of tumour necrosis factor (TNF) antagonists frequently arises from their use in rheumatic diseases, their first approved indications, and is later applied to psoriasis. Whether the risk of biological therapy is similar in psoriasis and rheumatoid arthritis has been considered a priority research question.To compare the safety profile of anti-TNF drugs in patients with rheumatoid arthritis and psoriasis.We compared two prospective safety cohorts of patients with rheumatoid arthritis and psoriasis that share methods (BIOBADASER and BIOBADADERM).There were 1248 serious or mortal adverse events in 16 230 person-years of follow-up in the rheumatoid arthritis cohort (3171 patients), and 124 in the 2760 person-years of follow-up of the psoriasis cohort (946 patients). Serious and mortal adverse events were less common in patients with psoriasis than in rheumatoid arthritis (incidence rate ratio of serious adverse events in psoriasis/rheumatoid arthritis: 0·6, 95% confidence interval 0·5-0·7). This risk remained after adjustment for sex, age, treatment, disease, hypertension, diabetes, hypercholesterolaemia and simultaneous therapy with methotrexate (hazard ratio 0·54, 95% confidence interval 0·47-0·61), and after excluding patients receiving corticosteroids. Patients with rheumatoid arthritis showed a higher rate of infections, cardiac disorders, respiratory disorders and infusion-related reactions, whereas patients with psoriasis had more skin and subcutaneous tissue disorders and hepatobiliary disorders.Patients with rheumatoid arthritis clinical practice have almost double the risk of serious adverse events compared with patients with psoriasis, with a different pattern of adverse events. Safety data from rheumatoid arthritis should not be fully extrapolated to psoriasis. These differences are likely to apply to other immune-mediated inflammatory diseases.
Abstract 13676: The Effect of Daily Aspirin on Cancer Incidence and Mortality in Type 2 Diabetic Patients in Japan: JPAD2 Study
Authors: Mio Sakuma, Takeshi Morimoto, Hisao Ogawa, Sadanori Okada, Hirofumi Soejima, Makiko Ohtorii, Masafumi Nakayama, Shiro Uemura, Masao Kanauchi, Naofumi Doi, Hideaki Jinnouchi, Seigo Sugiyama, Masako Waki, Takahiro Kawano, Yoshihiko Saito
Journal: Circulation (2013)

Objectives: To elucidate the epidemiology of cancer in patients with type 2 diabetes and assess the effect of daily aspirin on reduction in incidence and mortality of cancer in such patients. Metho...
18F-FDG Hypermetabolism in Spinal Cord Schistosomiasis
Authors: Mustafa Erkan Altinyay, Ashraf Alharthi, Ali H. Alassiri, Ghulam Mustafa Shah Syed
Journal: Clinical Nuclear Medicine (2015)

A 24-year-old Saudi man presented with progressive lower-back pain for 3 months followed by lower-limb weakness, numbness, and urinary retention. Cerebrospinal fluid examination revealed high-protein, elevated white blood cell count with lymphocyte predominance. MRI scan of the spine demonstrated heterogeneously enhancing longitudinal spinal cord lesion from T6 through T9. FDG-PET/CT demonstrated prominently hypermetabolic lesion in the spinal cord. He had laminectomy and spinal cord (intramedullary) biopsy. Pathology revealed Schistosoma mansoni ova.